Safe Surf Rated Back To Home Page Family Friendly Site
About
Bradford
  HIV/AIDS
Articles
  Alternative
Therapies
  HIV/AIDS
Videos
  HIV/AIDS
Links
  HIV/AIDS
News

Introduction:
Positively Positive
- Living with HIV
  Out
About
HIV
  Resume/
Curriculum Vitae:
HIV / AIDS Involvements
  Biography   HIV/AIDS
News Archive
HIV/AIDS News Bradford McIntyre
   



OraSure Closes Enrollment in Final Clinical Study for Rapid HIV Over-the-Counter Test

BETHLEHEM, Pa., Aug 9, 2011 (GlobeNewswire via COMTEX)- OraSure Technologies, Inc. the market leader in oral fluid diagnostics, announced today that it has closed enrollment for its multi-site clinical study of the Company's OraQuick(R) Rapid HIV-1/2 test for sale in the U.S. consumer or over-the-counter (OTC) market.

As previously announced, OraSure initiated the final phase of clinical testing for an in-home HIV self-test kit in December 2010. This phase consists of a multi-visit, blinded, unobserved user study in which individuals conduct unsupervised oral fluid self-testing using the investigational OTC version of the OraQuick ADVANCE(R) Rapid HIV-1/2 test. Once all subject visits are completed and study results are un-blinded, the performance of the OraQuick ADVANCE(R) Rapid HIV-1/2 Antibody test in an OTC setting will be compared with FDA-approved blood-based assay performance. One of the study objectives specified by the FDA was to identify at least 100 HIV infected, but undiagnosed individuals. In order to meet this requirement, the Company enrolled approximately 5,700 participants in the study across 20 clinical sites nationwide.

In planning for its FDA submission, the Company has decided to split its filing into three separate parts or modules, the timing of which will be spaced to allow the FDA sufficient review time between modules. This is an accepted technique used to start the formal review process as early as possible. The first of the three modules is expected to be submitted to FDA in the third quarter; the last of the modules, containing the results of the final clinical study, is expected to be submitted around the end of the year.

"We are extremely pleased to have reached this very significant milestone in our clinical study. The ease of use and non-invasive nature of the collection process makes our oral fluid rapid HIV Test an ideal candidate device for in-home use by consumers," said Douglas A. Michels, President and Chief Executive Officer of OraSure Technologies. "We anticipate the completion of the remainder of ongoing clinical study activities to occur sometime late in the third quarter, followed by data analyses in the fourth quarter. We look forward to continuing our work with the FDA and the healthcare community to make a home-use rapid HIV test available in the United States."

The Company also recently announced that the FDA and the Company's notified body in Europe have both granted an extension of shelf life to 30 months for the OraQuick HIV test. This is significant, not just for the professional market, but also for the over-the-counter market where the retail market typically requires a shelf life of 24 months or more.

OraQuick ADVANCE(R) is the first and only FDA-approved and CLIA-waived rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 in 20 minutes, using oral fluid, finger-stick or venipuncture whole blood or plasma specimens. As the market leader, OraQuick ADVANCE(R) is used extensively throughout the country in public health settings, hospitals, community-based organizations, and physician offices where HIV testing is conducted.

About OraSure Technologies

OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic devices and other technologies designed to diagnose critical medical conditions and diseases. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. These products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health. OraSure's products are sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. For more information on the Company, please go to www.orasure.com.

The OraSure Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=6440

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: OraSure Technologies, Inc.

 

Contacts:
OraSure Technologies, Inc.
Investor Contact:
Ronald H. Spair, Chief Financial Officer
610-882-1820
Investorinfo@orasure.com

Media Contact:
Jennifer Moritz
Zer0 to 5ive for OraSure Technologies
917-748-4006
jmoritz@0to5.com


"Reproduced with permission - OraSure Technologies, Inc"

OraSure Technologies, Inc
orasure.com


...positive attitudes are not simply 'moods'

Site Map

Contact Bradford McIntyre.

Web Design by Trevor Uksik

Copyright © 2003-2017 Bradford McIntyre. All rights reserved.

DESIGNED TO CREATE HIV & AIDS AWARENESS